1. Introduction {#sec1-vaccines-08-00175}
===============

Human papillomavirus (HPV) has been identified as one of the most common sexually transmitted infections (STIs) worldwide \[[@B1-vaccines-08-00175]\]. Most HPV infections appear to be transient and asymptomatic, but persistent infections can cause severe malignancies \[[@B2-vaccines-08-00175],[@B3-vaccines-08-00175]\], globally accounting for 90% of genital warts \[[@B4-vaccines-08-00175]\], 88% of anal cancers \[[@B5-vaccines-08-00175]\], 50% of penile cancers \[[@B5-vaccines-08-00175]\], and 31% of oral and pharyngeal cancers \[[@B5-vaccines-08-00175]\]. HPV and human immunodeficiency virus (HIV) could have a synergistic effect. Specifically, HPV infection, which may facilitate the invasion of pathogens, is a significant risk factor (3.5-times increased risk) for HIV acquisition \[[@B6-vaccines-08-00175]\]. Similarly, HIV infection can increase the risk of HPV infection and the failure of HPV clearance through weakening the immune function of the body \[[@B7-vaccines-08-00175]\].

Although there is an abundance of literature on HPV among men who have sex with men (MSM), data on HPV among very young MSM are still lacking. A systematic review that only included 698 MSM ≤ 25 years of age, all of whom were from North America and Europe, found that the rate of anal HPV-16 infection was up to 16% among MSM aged ≤ 20 years and up to 18% among those aged 21--25 years \[[@B8-vaccines-08-00175]\]. There is no published literature that focuses on HPV prevalence among young and teenage MSM in Asia. MSM attending university in China are a subgroup in the MSM community facing high risks of HIV and other STIs \[[@B9-vaccines-08-00175]\]. A systematic review found that the prevalence rates of HIV and syphilis among this population were 4.1% and 4.7%, respectively \[[@B10-vaccines-08-00175]\]. It was estimated that there were approximately 1.7 million MSM attending university in China aged 18--22 years in 2017 \[[@B11-vaccines-08-00175]\]. This group, which has a high prevalence of unprotected anal intercourse (UAI) and low condom use, are facing increasing risks of HIV and STIs \[[@B9-vaccines-08-00175]\]. Consistent with HIV infection, these behaviors may also put MSM attending university at potential risk of HPV transmission \[[@B7-vaccines-08-00175]\].

MSM are a neglected population in HPV prevention programs around the world. Three prophylactic HPV vaccines, directed against certain HPV types, are currently available for the prevention of HPV-related disease: the bivalent vaccine is recommended to females, and the quadrivalent and the nine-valent vaccines are recommended to both males and females \[[@B12-vaccines-08-00175]\]. However, current recommendations of HPV vaccination worldwide mainly target women, and very few countries provide HPV vaccination for men \[[@B13-vaccines-08-00175]\]. Despite the unavailability of a male HPV vaccination program, researchers have argued for targeted HPV vaccinations among teenage MSM in China \[[@B14-vaccines-08-00175]\]. Until that day comes, concrete evidence is needed. To provide evidence to support the promotion of HPV vaccination programs in young MSM in China, we conducted this study to characterize HPV infections and the associated risk factors among MSM attending university in China.

2. Materials and Methods {#sec2-vaccines-08-00175}
========================

2.1. Study Population {#sec2dot1-vaccines-08-00175}
---------------------

The methodology of the University Student HIV Test Intervention Study (the UniTest Study) has previously been published elsewhere \[[@B15-vaccines-08-00175]\]. Briefly, MSM attending university were recruited in four regions (Chongqing in Western China, Guangdong in Southern China, Shandong in Eastern China, and Tianjin in Northern China) from January to April in 2019 via advertising on the Internet, social network applications, peer referrals, and clinics. Participants were eligible if they were male, aged 16 years or older, university students, and self-reported to have sex with men. At enrollment, each participant provided informed consent. This study was conducted with the approval of the institutional review boards of Sun Yat-sen University (SYSU-SPH2018044).

2.2. Data Collection {#sec2dot2-vaccines-08-00175}
--------------------

Participants were required to finish a self-administrated online questionnaire to collect information regarding sociodemographics, sexual behavioral, HIV testing history, and alcohol and recreational drug use.

2.3. Sample Collection and Testing {#sec2dot3-vaccines-08-00175}
----------------------------------

Participants conducted a self-collected anal swab sample for HPV testing. The polymerase chain reaction (PCR) HPV genotyping test (Hybribio Biochemical Co., Ltd., Chaozhou, China) was used to determine the HPV-type distribution in specimens. The PCR test amplified the target HPV DNA for 37 anogenital HPV types, which included HPV-6, 11, 16, 18, 26, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59 61, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, and 84.

HIV testing was conducted by trained doctors with rapid HIV testing (Alere^®^ Determine HIV-1/2, Alere Medical Co., Ltd., Matsudo, Japan). Participants that tested positive for HIV were referred to local centers for disease control and prevention (CDC) for confirmation testing and subsequent services.

2.4. Variables and Definitions {#sec2dot4-vaccines-08-00175}
------------------------------

Sociodemographic variables of interest included age, education, academic performance (based on the self-reported grade point average (GPA)), dwelling location, sexual orientation, and the gender of sex partners. Sexual behaviors included age of first anal intercourse, number of sexual partners in the past 3 months, commercial sex history, compulsive sex history, engaging in group sex in the past 3 months, role of anal sex in the past 3 months, unprotected anal sex in the past 3 months, and condom use during last anal sex encounter.

The HPV detection variables consisted of type-specific HPV prevalence, any HPV type, high-risk HPV types, low-risk HPV types, single infection types, multiple infection types \[[@B16-vaccines-08-00175]\], and vaccine-preventable HPV types. Four-valent HPV types included HPV-6, 11, 16, and 18. Nine-valent HPV types included HPV-6, 11, 16, 18, 31, 33, 45, 52, and 58. High-risk HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. Low-risk HPV types included HPV-6, 11, 26, 34, 40, 42, 43, 44, 53, 54, 55, 57, 61, 66, 67, 69, 70, 71, 72, 73, 81, 82, 83, and 84 \[[@B17-vaccines-08-00175]\].

2.5. Statistical Analyses {#sec2dot5-vaccines-08-00175}
-------------------------

Descriptive statistics included summary measures of the mean or median and interquartile range (IQR) for continuous variables (e.g., age) and frequency tables for categorical variables (e.g., positive HPV detections). HPV prevalence was given as a percentage and corresponding 95% confidence intervals (CIs) for binomial proportions. Adjusted odds ratios (AORs) and 95% CIs of HPV infections were calculated according to characteristics using multivariate logistic regression models. Predictors with *p* \< 0.10 in the univariate analyses were included in the multiple logistic regression model to determine factors associated with HPV infections. The chi-square test with trends was used to demonstrate the significance of the trends in HPV prevalence with the time since first anal sex. Analyses were conducted using STATA MP 16 (StataCorp LLC, College Station, TX, USA).

3. Results {#sec3-vaccines-08-00175}
==========

3.1. Participant Characteristics {#sec3dot1-vaccines-08-00175}
--------------------------------

A total of 447 MSM attending university were enrolled in the study from January to April 2019. The demographic characteristics of the participants are shown in [Table 1](#vaccines-08-00175-t001){ref-type="table"}. Ages ranged from 17 to 27 years, with a median of 20 (IQR 19--21) years. Most were undergraduate students (342, 80.3%), self-reported above-average academic performances (338, 79.3%), and of homosexual orientation (364, 85.4%). Twelve participants (2.8%) were HIV-positive.

3.2. Sexual and High-Risk Behaviors {#sec3dot2-vaccines-08-00175}
-----------------------------------

[Table 1](#vaccines-08-00175-t001){ref-type="table"} also shows the sexual behaviors among MSM attending university by any HPV detection. Most of the participants (155, 96.9%) reported having sex with men only. A significantly higher percentage of participants with positive HPV diagnosis reported that the age of first anal intercourse (AFAI) with men was less than 18 years old (62.5% vs. 50.8%; *p* = 0.018) and having \> 2 sex partners (25.0% vs. 14.3%; *p* = 0.012). Participants with a positive HPV diagnosis practiced significantly more receptive anal sex (45.6% vs. 23.9%; *p* \< 0.001). Compared to HPV-negative participants, HPV-positive participants had a greater history of HIV testing (94.4% vs. 85.7%, *p* = 0.006). About one in five of all participants (83, 19.5%) had sex after drinking alcohol. Approximately one-third of all participants (126, 29.6%) reported recreational drug use.

3.3. Anal HPV Detection and Types {#sec3dot3-vaccines-08-00175}
---------------------------------

A total of 431 anal swabs were collected and tested for HPV types---Of which, five failed to test, with unsatisfactory samplings. [Table 2](#vaccines-08-00175-t002){ref-type="table"} shows the prevalence of anal HPV types among MSM attending university. The prevalence of anal HPV infections of any, high-risk, low-risk, and multiple types were 37.5%, 25.1%, 26.3%, and 19.0%, respectively. HPV-6 (8.9%), HPV-16 (8.7%), HPV-11 (7.5%), and HPV-18 (4.0%) were the most prevalent HPV types. Of those who were infected with any type of HPV, 79.4% (127/160) were infected with at least one type of nine-valent vaccine-preventable HPV type. The individual level of each HPV type is listed in [Supplementary Table S1](#app1-vaccines-08-00175){ref-type="app"}.

3.4. Risk Factors of Anal HPV Infection {#sec3dot4-vaccines-08-00175}
---------------------------------------

We found positive trends between positive anal HPV infections and time since first anal sex ([Figure 1](#vaccines-08-00175-f001){ref-type="fig"}). The proportion of participants with anal HPV of any type, any high-risk type, any two-valent (HPV-16/18) vaccine-preventable type, any four-valent vaccine-preventable type, and any nine-valent vaccine-preventable type increased significantly with time since the first anal sex (all *p* \< 0.05).

[Figure 2](#vaccines-08-00175-f002){ref-type="fig"} shows the factors associated with anal HPV infections among MSM attending university. In a multivariate analysis, participants enrolled in technical diploma programs (AOR: 1.88; 95% CI: 1.11--3.20), living in northern China (AOR: 1.98; 95% CI: 1.10--3.56), having more than two sexual partners (AOR: 2.29; 95% CI: 1.18--4.46), playing a receptive role (AOR: 7.16; 95% CI: 2.98--17.18) or a versatile role (AOR: 2.93; 95% CI: 1.29--6.66) in anal sex, and having an HIV testing history (AOR: 2.44; 95% CI: 1.11--5.36) were more likely to be infected with anal HPV of any type.

4. Discussion {#sec4-vaccines-08-00175}
=============

We found a high HPV prevalence among MSM attending university in China. The great majority of infected HPV types could have been prevented by HPV vaccination. To our knowledge, this is the first study to characterize the prevalence and types of anal HPV infections in this young population in China.

Our study found that the prevalence of any anal HPV infection among MSM attending university was 37.5%, which was lower than the overall prevalence of 52--66% among MSM with HIV-negative status in the general population in China \[[@B18-vaccines-08-00175],[@B19-vaccines-08-00175]\]. The possible reasons are as follows: compared with general MSM, MSM attending university are younger and have fewer sexual experiences, so they may be less exposed. In addition, they are generally more educated and may have a stronger sense of self-protection \[[@B10-vaccines-08-00175]\]. We found similar prevalence rates for HPV 6/11, 16/18, and 16 to that among MSM aged 20--29 years in another study that included 536 MSM in southern China \[[@B20-vaccines-08-00175]\].

According to our results, the majority of participants were infected with HPV vaccine-preventable types, indicating that promoting HPV vaccinations could potentially be an effective way to prevent HPV infections among this young population. In our study, HPV-16 and 18 were the most prevalent high-risk HPV types. Studies have found that the persistence of high-risk HPV types, specifically HPV-16/18, is an important risk factor for the development of anal cancer \[[@B21-vaccines-08-00175]\]. Fortunately, both four-valent and nine-valent HPV vaccines can protect MSM from these two HPV types. HPV-6 and 11 types, which can cause genital warts \[[@B4-vaccines-08-00175],[@B22-vaccines-08-00175]\], were the most prevalent low-risk HPV types among MSM attending university, and these two types could be protected by both the four-valent and nine-valent HPV vaccines. A previous study found that HPV vaccinations in males were highly effective in largely preventing anogenital warts and anal cancers \[[@B23-vaccines-08-00175]\]. The modeling analysis predicted that a vaccination program for males only with a certain coverage (80%) could achieve a reduction of 90% in HPV infections in MSM. In addition, the study also found targeted vaccination programs that commenced after sexual activity were much less effective, \[[@B24-vaccines-08-00175]\] suggesting that vaccinating males before their sex debut might substantially reduce the burden of HPV-related diseases.

Our study also found some risk factors associated with anal HPV infections. The proportion of anal HPV infections increased with time since the first anal intercourse among MSM attending university. With the increase of sexual activity, they are more likely to be exposed to HPV, which correspondingly increases the risk of HPV infection. Similar to the results in the general MSM population, playing a receptive role in anal sex and having multiple sex partners are also risk factors of anal HPV infections among MSM attending university \[[@B25-vaccines-08-00175],[@B26-vaccines-08-00175]\]. Furthermore, the use of geosocial networking gay applications (gay apps) is associated with risk behaviors, such as casual sex, group sex, drug use, etc., which lead to an increased risk of infection with HIV and HPV \[[@B27-vaccines-08-00175]\].

We found that participants enrolled in technical diploma programs were more likely to be infected with HPV than undergraduates. In the Chinese education system, the admission scores and learning tasks of technical diploma programs are lower than those of undergraduates \[[@B28-vaccines-08-00175]\]. Students in technical schools may have less academic burdens and have more free time than undergraduates, so they have comparatively more time to engage in sexual activities. Further studies may be needed to explain this result. Participants from the north had a higher proportion of HPV infections than those from the south, suggesting that there are regional differences in HPV infections. Similarly, in previous studies among the general MSM population in China, the proportions of anal HPV infections in northern cities (e.g., 71% for Beijing \[[@B29-vaccines-08-00175]\] and 62% for Tianjin \[[@B30-vaccines-08-00175]\]) were higher than those in southern cities (e.g., 48% Guangzhou \[[@B26-vaccines-08-00175]\] and 36% for Shenzhen \[[@B31-vaccines-08-00175]\]). The differences in HPV infections may be related to northern and southern Chinese living habits. In the north, group bathing in the bathhouse is preferred, while in the south, individual bathing at home is more common \[[@B32-vaccines-08-00175]\]. MSM who live in the north are more likely to engage in high-risk behaviors in the bathhouse, leading to a higher risk of HPV infections than those living in the south. We also found participants with a history of HIV testing had a higher prevalence of HPV infections. Previous studies found that serosorting may lead to reduced condom uses \[[@B33-vaccines-08-00175]\]. However, mathematical modeling suggested that inappropriate serosorting may increase the risk of STI acquisitions \[[@B34-vaccines-08-00175]\].

Our study had limitations. Firstly, this study was cross-sectional, thus limiting our ability to differentiate between transient HPV infections and persistent HPV infections. HPV detection at a single time cannot represent persistent HPV infections. A prospective study found that 66% and 90% of HPV infections would be cleared within 12 and 24 months, respectively, in men \[[@B35-vaccines-08-00175]\]. Consecutive HPV testing will be conducted at the 12-month visit to further understand the natural history of HPV infections among MSM attending university. Secondly, participants conducted self-operated anal samplings for HPV detection. Compared with professional-operated sampling, self-operated sampling may increase sampling failure but with the same accuracy \[[@B36-vaccines-08-00175]\]. The lessons learned will guide the implementation of home-based self-sampling for HPV and other STI testing in the future. Thirdly, the questionnaires were self-reported, and hence, recall bias might have occurred. Fourthly, we used only anal swab samples to test for HPV in cells, not anal biopsy samples to test for HPV in tissues. Swab sampling for detecting viruses is likely to sample HPV DNA present in the adjacent tissue or present only on the surface of the lesion, which may not necessarily be linked to the proliferation itself \[[@B16-vaccines-08-00175]\]. An existing systematic review found there was no difference in the HPV-16 detection rate between biopsies and cells, whereas the detection rate of other high-risk HPV types, including HPV-35, 51, and 68, was five times lower in biopsies than in cells \[[@B37-vaccines-08-00175]\]. However, biopsies can help diagnose precancerous lesions and could be considered in future studies. Finally, the method we used for HPV testing had high sensitivity and specificity in cervical samples \[[@B38-vaccines-08-00175]\], with a limit of detection of 500 IU/mL (international units per milliliter) \[[@B39-vaccines-08-00175]\]. Nevertheless, little is known about the consistency of this method in anal samples among MSM, indicating the need for further studies.

5. Conclusions {#sec5-vaccines-08-00175}
==============

Our study found a high prevalence of anal HPV infections among MSM attending university, especially for HPV vaccine-preventable types, suggesting that this population are a potential target group for HPV vaccinations. Prospective studies are needed to understand the natural history and influencing factors of HPV infections in this young population and to evaluate the effectiveness of HPV vaccinations in young males in China.
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vaccines-08-00175-t001_Table 1

###### 

Demographic characteristics and sexual behaviors among MSM attending university in China (*n* = 426).

  Variables                                      *n*   Any HPV-Positive (*n* = 160)   Any HPV-Negative (*n* = 266)   *p*          
  ---------------------------------------------- ----- ------------------------------ ------------------------------ ----- ------ ---------
  Age (years)                                                                                                                     
  ≤20                                            225   78                             48.8                           147   55.3   0.192
  \>20                                           201   82                             51.3                           119   44.7   
  Education                                                                                                                       
  Technical diploma                              84    40                             25.0                           44    16.5   0.034
  Undergraduate                                  342   120                            75.0                           222   83.5   
  Academic performance                                                                                                            
  Average and below                              88    33                             20.6                           55    20.7   0.990
  Above average                                  338   127                            79.4                           211   79.3   
  Regions                                                                                                                         
  Southern                                       117   34                             21.3                           83    31.2   0.058
  Eastern                                        100   40                             25.0                           60    22.6   
  Northern                                       113   52                             32.5                           61    22.9   
  Western                                        96    34                             21.3                           62    23.3   
  Sexual orientation                                                                                                              
  Other                                          20    6                              3.8                            14    5.3    0.106
  Bisexual                                       42    10                             6.3                            32    12.0   
  Homosexual                                     364   144                            90.0                           220   82.7   
  Gender of sex partners (*n* = 414)                                                                                              
  Only male                                      401   155                            98.1                           246   96.1   0.261
  Male and female                                13    3                              1.9                            10    3.9    
  Age at first anal intercourse (years)                                                                                           
  \<18                                           235   100                            62.5                           135   50.8   0.018
  ≥18                                            191   60                             37.5                           131   49.2   
  Number of sex partners (P3M)                                                                                                    
  0                                              103   31                             19.4                           72    27.1   0.012
  1--2                                           245   89                             55.6                           156   58.6   
  \>2                                            78    40                             25.0                           38    14.3   
  Group sex (P3M)                                                                                                                 
  No                                             349   129                            80.6                           220   82.7   0.589
  Yes                                            77    31                             19.4                           46    17.3   
  Role in anal sex (P3M) (*n* = 305)                                                                                              
  Receptive                                      100   57                             45.6                           43    23.9   \<0.001
  Versatile                                      150   59                             47.2                           91    50.6   
  Insertive                                      55    9                              7.2                            46    25.6   
  Unprotected anal intercourse (P3M)                                                                                              
  No                                             291   103                            64.4                           188   70.7   0.176
  Yes                                            135   57                             35.6                           78    29.3   
  HIV testing (lifetime)                                                                                                          
  No                                             47    9                              5.6                            38    14.3   0.006
  Yes                                            379   151                            94.4                           228   85.7   
  HIV status of sex partners (P3M) (*n* = 196)                                                                                    
  Negative                                       144   51                             64.6                           93    79.5   0.065
  Positive                                       5     3                              3.8                            2     1.7    
  Unknown                                        47    25                             31.6                           22    18.8   
  Sex after alcohol use (P12M)                                                                                                    
  No                                             343   119                            74.4                           224   84.2   0.013
  Yes                                            83    41                             25.6                           42    15.8   
  Recreational drug used in sex (lifetime)                                                                                        
  No                                             300   103                            64.4                           197   74.1   0.034
  Yes                                            126   57                             35.6                           69    25.9   
  HIV status                                                                                                                      
  Negative                                       414   151                            94.4                           263   98.9   0.012
  Positive                                       12    9                              5.6                            3     1.1    

P3M: past 3 months, P12M: past 12 months, MSM: men who have sex with men, HPV: human papillomavirus, and HIV: human immunodeficiency virus.

vaccines-08-00175-t002_Table 2

###### 

Type-specific anal HPV detection among MSM attending university in China (*n* = 426).

  Type of Infection                            Positive Cases   Prevalence (95% CI) (%)
  -------------------------------------------- ---------------- -------------------------
  Any HPV type                                 160              37.5 (32.9, 42.2)
  Any high-risk type                           107              25.1 (21.0, 29.3)
  Any low-risk type                            112              26.3 (22.1, 30.5)
  No. of HPV genotype detections                                
  Median and range                             Median: 2        Min: 1, Max: 9
  1 type                                       79               18.5 (14.8, 22.3)
  2 types                                      44               10.3 (7.4, 13.2)
  3 types                                      18               4.2 (2.3, 6.1)
  4+ types                                     19               4.5 (2.5, 6.4)
  Single infection                                              
  Single high-risk types                       35               8.2 (5.6, 10.8)
  Single low-risk types                        44               10.3 (7.4, 13.2)
  Mixed infection                                               
  Multiple high-risk types                     13               3.1 (1.4, 4.7)
  Multiple low-risk types                      9                2.1 (0.7, 3.5)
  Both high-risk and low-risk types            59               13.8 (10.6, 17.1)
  High-risk type                                                
  HPV 16                                       37               8.7 (6.0, 11.4)
  HPV 18                                       17               4.0 (2.1, 5.9)
  HPV 31                                       5                1.2 (0.1, 2.2)
  HPV 33                                       7                1.6 (0.4, 2.9)
  HPV 35                                       2                0.5 (−0.2, 1.1)
  HPV 39                                       11               2.6 (1.1, 4.1)
  HPV 45                                       9                2.1 (0.7, 3.5)
  HPV 51                                       16               3.8 (1.9, 5.6)
  HPV 52                                       16               3.8 (1.9, 5.6)
  HPV 56                                       8                1.9 (0.6, 3.2)
  HPV 58                                       9                2.1 (0.7, 3.5)
  HPV 59                                       1                0.2 (−0.2, 0.7)
  HPV 68                                       17               4.0 (2.1, 5.9)
  Low-risk type                                                 
  HPV 6                                        38               8.9 (6.2, 11.6)
  HPV 11                                       32               7.5 (5.0, 10.0)
  HPV 40                                       14               3.3 (1.6, 5.0)
  HPV 42                                       8                1.9 (0.6, 3.2)
  HPV 43                                       5                1.2 (0.1, 2.2)
  HPV 44                                       3                0.7 (−0.1, 1.5)
  HPV 53                                       7                1.6 (0.4, 2.9)
  HPV 54                                       6                1.4 (0.3, 2.5)
  HPV 55                                       3                0.7 (−0.1, 1.5)
  HPV 61                                       10               2.3 (0.9, 3.8)
  HPV 66                                       3                0.7 (−0.1, 1.5)
  HPV 67                                       10               2.3 (0.9, 3.8)
  HPV 69                                       1                0.2 (−0.2, 0.7)
  HPV 70                                       1                0.2 (−0.2, 0.7)
  HPV 71                                       1                0.2 (−0.2, 0.7)
  HPV 72                                       2                0.5 (−0.2, 1.1)
  HPV 73                                       5                1.2 (0.1, 2.2)
  HPV 81                                       8                1.9 (0.6, 3.2)
  HPV 82                                       5                1.2 (0.1, 2.2)
  HPV 84                                       6                1.4 (0.3, 2.5)
  Vaccine-preventable types                                     
  9vHPV                                        127              29.8 (25.5, 34.2)
  4vHPV                                        105              24.6 (20.5, 28.8)
  HPV 6/11                                     67               15.7 (12.3, 19.2)
  HPV 16/18                                    49               11.5 (8.5, 14.5)
  No. of vaccine-preventable type detections                    
  Median and range                             Median: 1        Min: 1, Max: 5
  1 type                                       95               22.3 (18.3, 26.3)
  2 types                                      25               5.9 (3.6, 8.1)
  3 types                                      4                0.9 (0, 1.9)
  4+ types                                     3                0.7 (−0.1, 1.5)

Note: HPV-26, 34, 57, and 83 were not detected. MSM: men who have sex with men; CI: confidence interval; HPV: human papillomavirus; HPV-6/11: HPV-6 or 11; HPV-16/18: HPV-16 or 18; 4vHPV: 4-valent HPV types, including HPV-6, 11, 16, and 18; and 9vHPV: 9-valent HPV types, including HPV-6, 11, 16, 18, 31, 33, 45, 52, and 58. High-risk HPV types include HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. Low-risk HPV types include HPV-6, 11, 26, 34, 40, 42, 43, 44, 53, 54, 55, 57, 61, 66, 67, 69, 70, 71, 72, 73, 81, 82, 83, and 84. Any type: any of the 37 HPV types mentioned above.
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